African descent is associated with slower CD4 cell count decline in treatment-naive patients of the Swiss HIV Cohort Study

AIDS

Volumn 23, Issue 10, 2009, Pages 1269-1276

  Müller, Viktor ^a,g   Von Wyl, Viktor ^b   Yerly, Sabine ^c   Böni, Jürg ^d   Klimkait, Thomas ^e   Bürgisser, Philippe ^f   Ledergerber, Bruno ^b   Günthard, Huldrych F ^b   Bonhoeffer, Sebastian ^g  

^a EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e UNIVERSITY OF BASEL   (Switzerland)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g ETH ZURICH   (Switzerland)

Author keywords

African descent; Disease progression; HIV subtypes; HIV 1; Host factors

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE COURSE; ETHNIC GROUP; GENDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NEGRO; PHYLOGENY; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIRUS LOAD;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PROGNOSIS; SWITZERLAND; VIRAL LOAD;

EID: 67651092167     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832d4096     Document Type: Article

References (35)

1. Kanki PJ, Hamel DJ, Sankale JL, Hsieh C, Thior I, Barin F, et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 1999;179:68-73.
2. Vasan A, Renjifo B, Hertzmark E, Chaplin B, Msamanga G, Essex M, et al. Different rates of disease progression of HlV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis 2006;42:843-852.
3. Kiwanuka N, Laeyendecker O, Robb M, Kigozi G, Arroyo M, McCutchan F, et al. Effect of human immunodeficiency virus type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda,with incident HIV-1 infection.J InfectDis2008; 197:707-713.
4. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007;317:944-947.
5. Joy R, Druyts EF, Brandson EK, Lima VD, Rustad CA, Zhang W, et al. Impact of neighborhood-level socioeconomic status on HIV disease progression in a universal healthcare setting. J Acquir Immune Defic Syndr 2008;47:500-505.
6. Langford SE, Ananworanich J, Cooper DA. Predictors of disease progression in HIV infection: a review. AIDS Res Ther 2007; 4:11. ]
7. Easterbrook PJ, Farzadegan H, Hoover DR, Palenicek J, Chmiel JS, Kaslow RA, Saah AJ. Racial differences in rate of CD4 decline in HIV-1-infected homosexual men. AIDS 1996; 10:1147-1155.
8. Anastos K, Gange SJ, Lau B, Weiser B, Detels R, Giorgi JV, et al. Association of race and gender with HIV-1 RNA levels and immunologic progression. J Acquir Immune Defic Syndr 2000; 24:218-226.
9. + lymphocyte count in a cohort of HIV-1-infected individuals. J Clin Virol 2003;26:101-107.
10. Saul J, Erwin J, Sabin CA, Kulasegaram R, Peters BS. The relationships between ethnicity, sex, risk group, and virus load in human immunodeficiency virus type 1 antiretroviral-naive patients. J Infect Dis 2001;183:1518-1521.
11. Silverberg MJ, Wegner SA, Milazzo MJ, McKaig RG, Williams CF, Agan BK, et al. Effectiveness of highly active antiretroviral therapy by race/ethnicity. AIDS2006;20:1531-1538.
12. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999;353:863-868.
13. von Wyl V, Yerly S, Boni J, Burgisser P, Klimkait T, Battegay M, et al. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 2007;167:1782-1790.
14. Muller V, Ledergerber B, Perrin L, Klimkait T, Furrer H, Telenti A, etal. Stable virulence levels in the HIV epidemic of Switzerland over two decades. AIDS 2006; 20:889-894.
15. Sabin CA, Devereux H, Phillips AN, Hill A, Janossy G, Lee CA, Loveday C. Course of viral load throughout HIV-1 infection. J Acquir Immune Defic Syndr 2000;23:172-177.
16. de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, Seebregts C, et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005; 21 :3797-3800.
17. Myers RE, Gale CV, Harrison A, Takeuchi Y, Kellam P. A statistical model for HIV-1 sequence classification using the subtype analyser (STAR). Bioinformatics 2005; 21 :3535- 3540.
18. Crawley MJ. The R book. Chichester, West Sussex: Wiley;2007
19. + T cell decrease and the year of human immunodeficiency virus (HIV) type 1 seroconversion among persons enrolled in the Swiss HIV cohort study. J Infect Dis 1999;180:1803-1808.
20. Holmes CB, Wood R, Badri M, Zilber S, Wang B, Maartens G, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 2006;42:464-469.
21. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-1170.
22. Damond F, Roquebert B, Benard A, Collin G, Miceli M, Yeni P, et al. Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR version 1.5 and the Roche COBAS Ampli- Prep/COBAS TaqMan HIV-1 assays. J Clin Microbiol 2007; 45:3436-3438.
23. Gueudin M, Plantier JC, Lemee V, Schmitt MP, Chartier L, Bourlet T, et al. Evaluation of the Roche Cobas TaqMan and Abbott realtime extraction-quantification systems for HIV-1 subtypes. J Acquir Immune Defic Syndr 2007;44:500-505.
24. Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 1995;333:751-756.
25. Galai N, Kalinkovich A, Burstein R, Vlahov D, Bentwich Z. African HIV-1 subtype C and rate of progression among Ethiopian immigrants in Israel. Lancet 1997; 349:180-181.
26. Del AmoJ, Petruckevitch A, Phillips A, Johnson AM, Stephenson J, Desmond N, etal. Disease progression and survival in HIV-1- infected Africans in London. AIDS 1998;12:1203-1209.
27. Lawn SD. AIDS in Africa: the impact of coinfections on the pathogenesis of HIV-1 infection. J Infect 2004;48:1-12.
28. Bentwich Z, Kalinkovich A, Weisman Z. Immune activation is a dominant factor in the pathogenesis of African AIDS. Immunol Today 1995;16:187-191.
29. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. JInfect Dis 1999; 179:859-870.
30. Leng Q, Borkow G, Weisman Z, Stein M, Kalinkovich A, Bentwich Z. Immune activation correlates better than HIV plasma viral load with CD4 T-cell decline during HIV infection. J Acquir Immune Defic Syndr 2001;27:389-397.
31. Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA, Lange JM, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003; 17:1881-1888.
32. + T-cell changes independent of viral load. Blood 2004; 104:942-947.
33. HeW, Neil S, Kulkarni H, Wright E, Agan BK, Marconi VC, etal. Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. Cell Host Microbe 2008;4:52-62.
34. Mayr FB, Spiel AO, LeitnerJM, FirbasC, Kliegel T, Jilma-Stohla- wetz P, et al. Duffy antigen modifies the chemokine response in human endotoxemia. Crit Care Med 2008; 36:159-165.
35. Douek DC, Roederer M, Koup RA. Emerging concepts in the immunopathogenesisofAIDS. AnnuRevMed2009; 60:471-484.